Published in Schizophr Res on April 30, 2012
Developing psychosis and its risk states through the lens of schizotypy. Schizophr Bull (2014) 0.88
Stress, Inflammation, and Cellular Vulnerability during Early Stages of Affective Disorders: Biomarker Strategies and Opportunities for Prevention and Intervention. Front Psychiatry (2014) 0.82
Impairments of working memory in schizophrenia and bipolar disorder: the effect of history of psychotic symptoms and different aspects of cognitive task demands. Front Behav Neurosci (2014) 0.75
The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry (2013) 4.16
Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry (2010) 3.88
Deep brain stimulation for psychiatric disorders. Dtsch Arztebl Int (2010) 2.60
Unilateral deep brain stimulation of the nucleus accumbens in patients with treatment-resistant obsessive-compulsive disorder: Outcomes after one year. Clin Neurol Neurosurg (2009) 2.57
The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorders. J Chem Neuroanat (2003) 2.08
Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry (2006) 1.69
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci (2004) 1.58
Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry (2009) 1.56
Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology (2004) 1.55
Deficient inhibitory cortical networks in antipsychotic-naive subjects at risk of developing first-episode psychosis and first-episode schizophrenia patients: a cross-sectional study. Biol Psychiatry (2012) 1.53
The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry (2005) 1.52
Intervention in at-risk states for developing psychosis. Eur Arch Psychiatry Clin Neurosci (2010) 1.50
Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull (2008) 1.44
[Early detection of psychosis in children and adolescents - have developmental particularities been sufficiently considered?]. Z Kinder Jugendpsychiatr Psychother (2011) 1.40
Prediction of psychosis by mismatch negativity. Biol Psychiatry (2010) 1.38
Neurocognitive indicators for a conversion to psychosis: comparison of patients in a potentially initial prodromal state who did or did not convert to a psychosis. Schizophr Res (2007) 1.38
Early detection and secondary prevention of psychosis: facts and visions. Eur Arch Psychiatry Clin Neurosci (2004) 1.34
Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. Biol Psychiatry (2008) 1.31
Probably at-risk, but certainly ill--advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res (2010) 1.26
Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry (2007) 1.21
Neural correlates of working memory dysfunction in first-episode schizophrenia patients: an fMRI multi-center study. Schizophr Res (2006) 1.21
Impaired mismatch negativity generation in prodromal subjects and patients with schizophrenia. Schizophr Res (2005) 1.20
Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogues Clin Neurosci (2010) 1.17
Gray matter abnormalities in subjects at ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls. Psychiatry Res (2009) 1.15
Increased neural response related to neutral faces in individuals at risk for psychosis. Neuroimage (2007) 1.15
Prediction and prevention of schizophrenia: what has been achieved and where to go next? World Psychiatry (2011) 1.15
Subjective and objective neuropsychological abnormalities in a psychosis prodrome clinic. Br J Psychiatry Suppl (2002) 1.13
Whither the attenuated psychosis syndrome? Schizophr Bull (2012) 1.12
Binocular depth inversion as a paradigm of reduced visual information processing in prodromal state, antipsychotic-naïve and treated schizophrenia. Eur Arch Psychiatry Clin Neurosci (2009) 1.11
Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry (2010) 1.11
Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr Bull (2014) 1.10
Neuropsychological profiles in different at-risk states of psychosis: executive control impairment in the early--and additional memory dysfunction in the late--prodromal state. Schizophr Bull (2010) 1.10
Neurocognitive functioning in subjects at risk for a first episode of psychosis compared with first- and multiple-episode schizophrenia. J Clin Exp Neuropsychol (2006) 1.10
Disability in people clinically at high risk of psychosis. Br J Psychiatry (2010) 1.10
Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res (2007) 1.09
Genome-wide association study in German patients with attention deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet (2011) 1.09
Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness. Schizophr Res (2006) 1.08
Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry (2009) 1.06
Basic symptoms and the prediction of first-episode psychosis. Curr Pharm Des (2012) 1.05
Reliability and validity of Quality of Life assessed by the Short-Form 36 and the Modular System for Quality of Life in patients with schizophrenia and patients with depression. Psychiatry Res (2003) 1.05
Axis I diagnoses and transition to psychosis in clinical high-risk patients EPOS project: prospective follow-up of 245 clinical high-risk outpatients in four countries. Schizophr Res (2012) 1.04
Interventions in the initial prodromal states of psychosis in Germany: concept and recruitment. Br J Psychiatry Suppl (2005) 1.03
From nature versus nurture, via nature and nurture, to gene x environment interaction in mental disorders. Eur Child Adolesc Psychiatry (2009) 1.02
German research network on schizophrenia-bridging the gap between research and care. Eur Arch Psychiatry Clin Neurosci (2003) 1.01
Self-reported psychotic-like experiences are a poor estimate of clinician-rated attenuated and frank delusions and hallucinations. Psychopathology (2013) 1.01
Predictors of relapse in the year after hospital discharge among patients with schizophrenia. Psychiatr Serv (2012) 1.00
Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Interv Psychiatry (2007) 1.00
CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS One (2007) 0.99
Pharmacological intervention in the initial prodromal phase of psychosis. Eur Psychiatry (2005) 0.99
Determinants of subjective quality of life in post acute patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci (2003) 0.99
Evaluation of the German WPA "program against stigma and discrimination because of schizophrenia--Open the Doors": results from representative telephone surveys before and after three years of antistigma interventions. Schizophr Res (2007) 0.99
Basic symptoms in early psychotic and depressive disorders. Br J Psychiatry Suppl (2007) 0.98
The near Babylonian speech confusion in early detection of psychosis. Schizophr Bull (2011) 0.98
Kraepelin and psychotic prodromal conditions. Eur Arch Psychiatry Clin Neurosci (2008) 0.96
Auditory P300 in individuals clinically at risk for psychosis. Int J Psychophysiol (2008) 0.94
'A rose is a rose is a rose', but at-risk criteria differ. Psychopathology (2012) 0.94
Integrated care in patients with schizophrenia: results of trials published between 2011 and 2013 focusing on effectiveness and efficiency. Curr Opin Psychiatry (2013) 0.93
Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. Anal Biochem (2006) 0.93
Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol (2008) 0.93
Obsessive-compulsive disorder: development of demand-controlled deep brain stimulation with methods from stochastic phase resetting. Neuropsychopharmacology (2003) 0.93
Successful deep brain stimulation of the nucleus accumbens in severe alcohol dependence is associated with changed performance monitoring. Addict Biol (2011) 0.92
What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. Eur Arch Psychiatry Clin Neurosci (2014) 0.92
Cognitive-behavioral therapy in the pre-psychotic phase: an exploratory study. Psychiatry Res (2005) 0.91
Neurophysiological correlates of impaired facial affect recognition in individuals at risk for schizophrenia. Schizophr Bull (2011) 0.91
Familiality of obsessive-compulsive disorder in nonclinical and clinical subjects. Am J Psychiatry (2006) 0.91
Recent approaches to psychological interventions for people at risk of psychosis. Eur Arch Psychiatry Clin Neurosci (2006) 0.91
Subjective quality of life in subjects at risk for a first episode of psychosis: a comparison with first episode schizophrenia patients and healthy controls. Schizophr Res (2005) 0.91
Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry (2012) 0.90
Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. Am J Psychiatry (2014) 0.90
Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response? Eur Neuropsychopharmacol (2011) 0.89
Neurocognitive indicators of clinical high-risk states for psychosis: a critical review of the evidence. Neurotox Res (2010) 0.89
Orienting of attention in unmedicated patients with schizophrenia, prodromal subjects and healthy relatives. Schizophr Res (2007) 0.89